Work

Abstract CT232: SU2C Phase Ib study of the PI3K-alpha inhibitor BYL719 (alpelisib) with letrozole in ER+/HER2-metastatic breast cancer

Year: 2015

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2015-ct232

Authors: Ingrid A. Mayer, Vandana Abramson, Justin Balko, Melinda Sanders, Dejan Juric, David Solit, Yisheng Li, Lewis Cantley, Eric Winer, Carlos Arteaga

Institutions: Vanderbilt University Medical Center, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, The University of Texas MD Anderson Cancer Center, Weill Cornell Medicine, Dana-Farber Cancer Institute

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1469597457

Cites:

Cited by: 3

Related to: 10